Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Trastuzumab Deruxtecan Hormone Receptor Positive Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Deruxtecan Inflammatory Breast Carcinoma	Filipa Lynce, MD	P2	CCC (53)
Trastuzumab Deruxtecan Ovarian Carcinoma	Yonsei University	P2	CCC (53)
Trastuzumab Deruxtecan Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer	AstraZeneca	P2	CCC (53)
Trastuzumab Deruxtecan Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer	AstraZeneca	P2	CCC (53)
Trastuzumab Deruxtecan Metastatic Prostate Carcinoma	Washington D.C. Veterans Affairs Medical Center	P2	CCC (53)
Trastuzumab Deruxtecan Rectal Cancer	Gruppo Oncologico del Nord-Ovest	P2	CCC (53)
Trastuzumab Duocarmazine Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Duocarmazine Hormone Receptor Negative Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Duocarmazine Hormone Receptor Positive Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Emtansine Angiosarcoma	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Emtansine Cervical Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Colon Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Endometrial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Epithelial Tumor	University Health Network, Toronto	P2	CCC (53)
Trastuzumab Emtansine Estrogen-Receptor Negative Breast Cancer	Jules Bordet Institute	P2	CCC (53)
Trastuzumab Emtansine ER Positive Breast Cancer	Dana-Farber Cancer Institute	P2	CCC (53)
Trastuzumab Emtansine Carcinoma Of Esophagus	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Estrogen-Receptor Positive Breast Cancer	Dana-Farber Cancer Institute	P2	CCC (53)
Trastuzumab Emtansine Gastric Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Head And Neck Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Heart Failure	Population Health Research Institute	P2	CCC (53)
Trastuzumab Emtansine Hematopoietic And Lymphoid Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Hormone Receptor Negative Tumor	QuantumLeap Healthcare Collaborative	P2	CCC (53)
Trastuzumab Emtansine Hormone Receptor Positive	Spanish Breast Cancer Research Group	P2	CCC (53)

Showing 476 to 500 of 1,027 assets

PreviousPage 20 of 42Next